Alvotech fails pre-approval inspection for its proposed Humira interchangeable biosimilar

Zachary Brennan

Senior Editor

Almost a dozen new Humira biosimilars will finally launch in the US next year, beginning with Amgen’s in January (almost four years behind Europe), but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alvotech fails pre-approval inspection for its proposed Humira interchangeable biosimilar

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Updated: Novartis claims best earnings in years, validating shift to pure-play strategy

AbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up Humira's mantle

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

Daiichi Sankyo taps new CEO, aims to build up ADC franchise

Vertex's non-opioid pain drug is approved by FDA, bringing first of new class to market

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

Alvotech fails pre-ap­proval in­spec­tion for its pro­posed Hu­mi­ra in­ter­change­able biosim­i­lar

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Alvotech fails pre-approval inspection for its proposed Humira interchangeable biosimilar